Share Answers from the Lab
Share to email
Share to Facebook
Share to X
By Mayo Clinic Laboratories
5
2121 ratings
The podcast currently has 325 episodes available.
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guest Donald Thomas, M.D., a rheumatologist and lupus researcher. They discuss how Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, is enhancing the care and quality of life for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
John Mills, Ph.D., and Divyanshu Dubey, M.B.B.S., explain how Mayo Clinic Laboratories' new test panel can distinguish among various potential causes of demyelinating neuropathies. Test results are important for managing these devastating autoimmune conditions.
Show notes
Speaker 3: (00:32)
Would you provide a little background on yourself, Dr. Mills?
Speaker 3: (01:19)
Dr. Dubey?
Speaker 3: (02:07)
Can you give a brief overview of our demyelinating test and recommended use?
Speaker 3: (03:52)
Can you discuss how this new test will assist in a patient's journey?
Speaker 3: (05:46)
Can you tell us some of the unique features of this test?
Speaker 3: (08:09)
Dr. Dubey, as a neurologist, how does this test set us apart in the market?
Speaker 3: (11:05)
Could you summarize the benefits of having both a demyelinating panel and an axonal panel?
Speaker 3: (11:40)
Why should a patient have an axonal or demyelinating test versus a sensory and motor test for peripheral neuropathy?
In this episode of “Answers From the Lab,” William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, is joined by special guests Bernard Rubin, D.O., MPH, chief medical officer of Progentec Diagnostics, and Melissa Munroe, M.D., Ph.D., chief scientific officer and principal investigator of Progentec Diagnostics. They discuss Mayo Clinic Laboratories’ suite of innovative lupus testing, offered in collaboration with Progentec Diagnostics, for patients affected by systemic lupus erythematosus (SLE).
Their discussion includes:
Ann Moyer, M.D., Ph.D., explains how Mayo Clinic Laboratories' unique genetic tests identify patients at high risk of severe reactions to fluoropyrimidines — a type of chemotherapy drug. Test results can guide clinical decision-making for safer cancer treatment.
Speaker 3: (00:32)
Would you tell us a little bit about yourself and your history with this testing?
Speaker 3: (01:25)
Would you tell us a little more about this assay?
Speaker 3: (04:57)
Which patients should have this testing and when should it be performed?
Speaker 3: (05:30)
What alternative tests exist and how do they compare?
Speaker 3: (06:28)
How are the results used in patient care?
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories, to discuss the latest advancements in Alzheimer’s disease testing and treatment.
Their discussion includes:
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They cover current trends, pain points, and opportunities for growth in the lab and diagnostics market.
Their discussion includes:
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by Matthew Binnicker, Ph.D., professor of laboratory medicine and pathology and clinical virologist at Mayo Clinic. They discuss the upsurge of mpox cases, particularly in Africa, and why the World Health Organization has declared it a public health emergency of international concern.
Specific topics of discussion include:
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss what’s new and ongoing with pathogens and infections.
Their discussion includes:
Maria Alice Willrich, Ph.D., and Melissa Snyder, Ph.D., explain how Mayo Clinic Laboratories' unique risankizumab panel measures levels of both that drug and its antibodies in patients' blood. The results can better guide the management of patients with inflammatory bowel disease.
Speaker 4: (00:32)
Please give the audience a little information about yourself and your background.
Speaker 4: (02:12)
Please give the audience a brief overview of this assay.
Speaker 4: (04:34)
Which patients should have this testing and when should it be performed?
Speaker 4: (05:50)
What alternative testing options are available and how do these compare?
Speaker 4: (06:47)
How are the results used in patient care?
In this episode of “Answers From the Lab,” host Bobbi Pritt, M.D., chair of the Division of Clinical Microbiology at Mayo Clinic, is joined by William Morice II, M.D., Ph.D., CEO and president of Mayo Clinic Laboratories. They discuss insights from Dr. Morice’s recent travels abroad, including biomanufacturing, diagnostics, cybersecurity, and supply chain activities.
Their discussion includes:
The podcast currently has 325 episodes available.
38,433 Listeners
2,012 Listeners
6,209 Listeners
458 Listeners
43,318 Listeners
257 Listeners
85,218 Listeners
110,255 Listeners
55,893 Listeners
77 Listeners
6,194 Listeners
17 Listeners
586 Listeners
3,674 Listeners